Vaccine | Recommended ages for routine administration | Dose | Route | Preferred site |
Monoclonal antibody | ||||
RSV monoclonal antibody (If birthing parent did not receive RSV vaccine during pregnancy*) |
|
| IM | |
Inactivated vaccines and/or toxoids | ||||
Diphtheria, tetanus, acellular pertussis |
|
| IM |
|
Haemophilus influenzae type b |
|
| IM |
|
Hepatitis A |
|
| IM |
|
Hepatitis BΔ |
|
| IM |
|
Human papillomavirus◊ |
|
| IM |
|
Influenza, inactivated |
|
| IM |
|
Meningococcal conjugate vaccine, quadrivalent (MenACWY-CRM [Menveo], MenACWY-TT [MenQuadfi]) |
|
| IM |
|
Meningococcal serogroup B¥ (MenB-4C [Bexsero], MenB-FHbp [Trumenba]) |
|
| IM |
|
Pneumococcal conjugate vaccine |
|
| IM |
|
Poliovirus, inactivated |
|
| IM or subcutaneous |
|
Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis |
|
| IM |
|
Inactivated combination vaccines | ||||
DTaP-HepB-IPV vaccine (Pediarix) |
|
| IM |
|
DTaP-IPV/Hib vaccine (Pentacel) |
|
| IM |
|
DTaP-IPV-Hib-HepB vaccine (Vaxelis) |
|
| IM |
|
DTaP-IPV vaccine (Kinrix, Quadricel) |
|
| IM |
|
MenACWY-TT/MenB-FHbp (Penbraya) |
|
| IM |
|
Live attenuated vaccines | ||||
Influenza |
|
| Intranasal | |
Measles, mumps, and rubella (M-M-R II, Priorix) |
|
| Subcutaneous or IM (M-M-R II vaccine only) |
|
Rotavirus |
|
| Orally | |
|
| Orally | ||
Varicella |
|
| Subcutaneous or IM |
|
Dengue† |
|
| Subcutaneous |
|
Live attenuated combination vaccines | ||||
MMRV vaccine (ProQuad) Available only for children ≤12 years |
|
| Subcutaneous or IM |
|
Viral component vaccines | ||||
COVID-19 vaccines |
|
COVID-19: coronavirus disease 2019; DTaP: diphtheria, tetanus, acellular pertussis; HepB: hepatitis B; Hib: Haemophilus influenzae type b; IM: intramuscular; IPV: inactivated poliovirus; MenACWY: meningococcal serogroup A, C, W, Y vaccine; MenB: meningococcal serogroup B vaccine; MMR: measles, mumps, and rubella; MMRV: measles, mumps, rubella, and varicella; RSV: respiratory syncytial virus; RV1: attenuated human rotavirus vaccine; RV5: pentavalent human-bovine rotavirus reassortant vaccine.
* Refer to separate UpToDate content for the criteria that constitute receipt of RSV vaccine during pregnancy.
¶ The 6-month dose may not be necessary, depending upon vaccine formulation.
Δ The recommended schedule varies with birth weight and HepB surface antigen status of the mother. Refer to UpToDate content on HepB vaccines for infants for details.
◊ If the human papillomavirus series is initiated at age ≥15 years, 3 doses should be administered: The 2nd dose is recommended 1 to 2 months after the 1st dose, and the 3rd dose is recommended 6 months after the 1st dose.
§ Refer to UpToDate content on seasonal influenza vaccines for children for additional information.
¥ MenB vaccines are not routinely recommended for adolescents who are not at increased risk for meningococcal disease. However, they may be given to adolescents and young adults age 16 through 23 years.
‡ The fatty tissue over the upper-outer triceps is the preferred site. The fatty tissue over the anterolateral thigh is an acceptable alternative.
† For children who live in dengue endemic United States territories and sovereign states in free association with the United States (American Samoa, Federated States of Micronesia, Republic of Marshall Islands, Republic of Palau, Puerto Rico, United States Virgin Islands) and have laboratory confirmation of previous Dengue infection. Refer to the ACIP recommendations and https://www.cdc.gov/dengue/hcp/vaccine/.
** Administration of MMRV as the first dose of measles-containing vaccine at age 12 through 15 months has been associated with an increased risk of febrile seizures. The Centers for Disease Control and Prevention and American Academy of Pediatrics suggest that MMR and varicella vaccines be administered as separate injections at age 12 through 15 months unless the parents/caregivers have a preference for MMRV. Refer to UpToDate content on MMR and varicella vaccination for children for additional details.